DOCSLIB.ORG

Cyclobenzaprine and Back Pain: a Meta-Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyclobenzaprine and Back Pain: a Meta-Analysis ORIGINAL INVESTIGATION Cyclobenzaprine and Back Pain A Meta-analysis Robert Browning, MD; Jeffrey L. Jackson, MD, MPH; Patrick G. O’Malley, MD, MPH Background: Back pain is a common problem for which 14 as were those treated with placebo. Slightly fewer than cyclobenzaprine hydrochloride is frequently pre- 3 individuals (2.7; 95% confidence interval, 2.0-4.2) scribed. needed treatment for 1 to improve. The magnitude of this improvement was modest, with an effect size of 0.38 to Objective: To perform a systematic review of cyclo- 0.58 in all 5 outcomes (local pain, muscle spasm, ten- benzaprine’s effectiveness in the treatment of back pain. derness to palpation, range of motion, and activities of daily living). Treatment efficacy for these 5 outcomes was Methods: We searched MEDLINE, PsycLIT, CINAHL, greatest early, in the first few days of treatment, declin- EMBASE, AIDSLINE, HEALTHSTAR, CANCERLIT, the ing after the first week. Patients receiving cyclobenzap- Cochrane Library, Micromedex, Federal Research in rine also experienced more adverse effects, the most com- Progress, and the references of reviewed articles, and con- mon being drowsiness. tacted Merck, Sharpe and Dohme for English-language, randomized, placebo-controlled trials of cyclobenzap- Conclusions: Cyclobenzaprine is more effective than rine in adults with back pain. Outcomes included global placebo in the management of back pain; the effect is improvement and 5 specific domains of back pain (local modest and comes at the price of greater adverse effects. pain, muscle spasm, range of motion, tenderness to pal- The effect is greatest in the first 4 days of treatment, sug- pation, and activities of daily living). Study quality was gesting that shorter courses may be better. Studies com- assessed using the methods of Jadad. Summary out- paring the relative value of acetaminophen, nonsteroidal comes were obtained using a random-effects model. anti-inflammatory drugs, and cyclobenzaprine individu- ally and in combination in the treatment of back pain Results: Patients treated with cyclobenzaprine were are needed. nearly 5 times (odds ratio, 4.7; 95% confidence interval, 2.7-8.1) as likely to report symptom improvement by day Arch Intern Med. 2001;161:1613-1620 ACK AND NECK pain are com- Agency for Health Care Policy and Re- mon, accounting for 1.8% search (AHCPR) back pain guidelines,11 of all office visits in the released in 1994, suggest that acetamino- United States, approxi- phen is the safest and most effective medi- mately 200000 visits per cation for acute low back problems and year.B1 Among adults presenting with a that nonsteroidal anti-inflammatory drugs physical complaint, these problems are sec- (NSAIDs), although effective, should be ond only to upper respiratory tract infec- used sparingly since they can cause gas- tions as a reason for seeking medical care.2-4 trointestinal irritation, ulceration, and, less Since only about a fourth of patients with commonly, renal or allergic problems. The a physical symptom seek medical atten- panel recommended that muscle relax- tion,5 back and neck pain are even more ants not be used, because they were be- prevalent in the general population. It is lieved to be no more effective than NSAIDs; estimated that up to half of working adults their use in combination with acetamino- experience back pain each year,6 and 70% phen or NSAIDs had no additional dem- From the Departments of of all adults experience it at some time in onstrated benefit; and adverse effects, in- Medicine, National Naval their life.7 Most episodes are self-limited, cluding drowsiness, are common. Medical Center (Dr Browning), with 90% of patients recovering to full ac- Despite these guidelines, cyclobenza- and Uniformed Services tivity within 1 month.8 Even among the prine hydrochloride is still commonly used University of the Health 2% with sciatica, more than half improve in the management of acute back pain. Na- Sciences (Drs Jackson and substantially within 6 weeks and only 5% tional Ambulatory Medical Care Survey data O’Malley), Bethesda, Md; and 6 the Department of Medicine, to 10% eventually require surgery. from 1995 to 1997 indicate that among 7 Walter Reed Army Medical Guidelines for treating back pain rec- million ambulatory visits to primary care Center, Washington, DC ommend empirical therapy, with no ra- physicians for back pain, 13% of the pa- (Drs Jackson and O’Malley). diologic evaluation in most patients.7-10 The tients received cyclobenzaprine.12 Be- (REPRINTED) ARCH INTERN MED/ VOL 161, JULY 9, 2001 WWW.ARCHINTERNMED.COM 1613 ©2001 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/04/2021 MATERIALS AND METHODS graphics, number of participants enrolled, follow-up losses, adverse effects, and outcomes. Outcomes were extracted as either dichotomous or continuous variables (or both), de- For this review, we searched MEDLINE (January 1966- pending on how they were reported in the studies. December 1999), PsycLIT (November 1887-December All analyses were done using Stata 6.0 (Stata Corp, Col- 1999), CINAHL (1982-1999), EMBASE (January 1974 lege Station, Tex). Assessment for publication bias was done December 1999), AIDSLINE, HEALTHSTAR, CANCERLIT, using the methods of Egger et al14; heterogeneity was as- and Micromedex using the text word and keyword (all lan- sessed visually with Galbraith plots15 andQ(x2) statistics guages) cyclobenzaprine. An additional search using the using the methods of Mantel-Haenszel.16 Although most Medical Subject Heading terms dibenzocycloheptenes and pooled results were homogeneous, the more conservative ran- propylamines was combined with the following text words: dom-effects model using the method of DerSimonian and back pain, backache, low back pain, lumbago, acute muscle Laird16 was used to calculate summary odds ratios (ORs), spasm,ormuscle spasm. We used the Cochrane Library, risk differences, and standardized mean differences. Analy- searching the clinical trials registry for randomized trials, sis of the continuous outcome involved comparing stan- and the Cochrane Database of Systematic Reviews for sys- dardized differences in means between control and treat- tematic reviews. We searched Federal Research in Progress ment groups. Mean outcome scores for the 5 continuous to identify unpublished literature. We searched the refer- outcomes (local pain, muscle spasm, tenderness to palpa- ences of reviewed articles for additional articles missed by tion, range of motion, and activities of daily living) were stan- the computerized database search. We also contacted Merck, dardized by dividing the means for the placebo and treat- Sharpe and Dohme, West Point, Pa. ment groups in each study by their SD. The differences Studies were screened for inclusion (through review between these standardized outcome scores, also known as of the abstract or the published article, if the abstract was effect sizes, were calculated for each study and analyzed. This unclear) based on the following criteria: randomization, pla- approach is especially appropriate when studies measure the cebo control, at least one group receiving cyclobenzap- same concept but use various continuous scales. By stan- rine, and measurable outcomes reported. Studies evaluat- dardization, the study results are transformed to a common ing cyclobenzaprine in the treatment of muscle spasticity scale (SD units) that facilitates pooling. of central nervous system origin were excluded from this Several measures of the sensitivity of the meta-anal- meta-analysis. Authors of abstracts that appeared promis- ysis results to various assumptions were conducted. The ing were contacted and asked to provide data. sensitivity of the results to the existence of unpublished stud- Included study quality was assessed using a 6-item ies was assessed using a “file drawer” test,17 conducted by instrument developed and validated by Jadad et al.13 The 6 determining how many studies with negative results (OR, items in this scale include description of randomization, 1.0; standardized mean difference, 0), each with variance adequacy of blinding, description of withdrawals and and size equal to the average found among the included dropouts, appropriateness of statistical analysis, descrip- studies, would have to exist to negate our findings. A test tion of inclusion and exclusion criteria, and method for for the relative influence of each individual study on the assessing adverse treatment effects. The study quality was results was determined by sequentially dropping indi- assessed independently in duplicate, with substantial inter- vidual studies and calculating summary measures. We ex- rater agreement (k, 0.79). Disagreements were arbitrated plored several sources of heterogeneity, including year of by consensus. publication, type of syndrome (acute vs chronic back pain), Abstracted data included setting, country of origin, treat- study quality scores, and duration and dose of therapy us- ment characteristics (dose, duration, and follow-up), demo- ing metaregression. cause cyclobenzaprine is frequently used for the manage- all studies were randomized and placebo controlled, there ment of back pain, we conducted a meta-analysis of the were several specific quality problems (Table 1), includ- English-language literature to assess the efficacy of this ing inadequate description of the randomization method treatment option. in 9,18,21,22,25,30-32,35,37 failure to describe the placebo as iden- tical to the active medicine
Load more

Recommended publications
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Case Report Carbamazepine Toxicity Following Oxybutynin And
    Spinal Cord (2005) 43, 252–255 & 2005 International Spinal Cord Society All rights reserved 1362-4393/05 $30.00 www.nature.com/sc Case Report Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report T Vander*,1, H Odi1, V Bluvstein1, J Ronen1,2 and A Catz1,2 1Department of Spinal Rehabilitation, Loewenstein Rehabilitation Hospital, Raanana, Israel; 2Tel-Aviv University, Tel-Aviv, Israel Objective: To report a case of Carbamazepine toxicity following the administration of Oxybutynin and Dantrolene. Study design: A case report. Setting: The Spinal Rehabilitation Department, Loewenstein Hospital, Raanana, Israel. Methods: A patient with C6D tetraplegia who sustained intoxication because of drug interaction is presented. She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity. After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication. Trying to adjust the treatment to the patient’s requirements, Carbamazepine together with Oxybutynin and Dantrolene was readministrated in lower doses. Results: The combination of these drugs, even small doses, caused toxicity. Adding Dantrolene and Oxybutynin elevated the blood level of Carbamazepine, possibly by inhibition of cytochrome P450. Conclusion: A possible pharmacokinetic interaction between Dantrolene and Oxybutynin should be borne in mind when considering Carbamazepine medication for a patient with a spinal cord lesion. Spinal Cord (2005) 43, 252–255. doi:10.1038/sj.sc.3101689; Published online 1 February 2005 Keywords: Carbamazepine; Oxybutynin; Dantrolene; drug interaction; cytochrome P450 Introduction Both Oxybutynin chloride and Dantrolene sodium are be required when patients have concomitant post- widely used in patients with spinal cord lesion (SCL).
    [Show full text]
  • Parkinson's Disease Fact Sheet
    Parkinson’s Disease Fact Sheet About Parkinson’s Disease Parkinson’s disease is a progressive, incurable neurological disorder associated with a loss of dopamine-generating cells in the brain. It is primarily associated with progressive loss of motor control, but it results in a complex array of symptoms, including many non-motor symptoms. Parkinson’s impacts an estimated one million people in the United States. Critical Clinical Care Considerations • To avoid serious side effects, Parkinson’s patients need their medications on time, every time — do not skip or postpone doses. • Write down the exact times of day medications are to be administered so that doses are given on the same schedule the patient follows at home. • Do not substitute Parkinson’s medications or stop levodopa therapy abruptly. • Resume medications immediately following procedures, unless vomiting or severely incapacitated. • If an antipsychotic is necessary, use pimavanserin (Nuplazid), quetiapine (Seroquel) or clozapine (Clozaril). • Be alert for symptoms of dysphagia (trouble swallowing) and risk of pneumonia. • Ambulate as soon as medically safe. Patients may require assistance. Common Symptoms of Parkinson’s Disease Motor Non-Motor • Shaking or tremor at rest • Depression • Bradykinesia or freezing (being stuck • Anxiety in place when attempting to walk) • Constipation • Low voice volume or muffled speech • Cognitive decline and dementia • Lack of facial expression • Impulse control disorders • Stiffness or rigidity of the arms, legs • Orthostatic hypotension or
    [Show full text]
  • Development and Validation of a LC-MS/MS Method for Detection and Quantification of 18 Antidepressants in Whole Blood
    City University of New York (CUNY) CUNY Academic Works Student Theses John Jay College of Criminal Justice Spring 6-2019 Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood Linda Kim CUNY John Jay College, [email protected] How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/jj_etds/106 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood A Thesis Presented in Partial Fulfillment of the Requirements for the Degree of Master of Science in Forensic Science, John Jay College of Criminal Justice, City University of New York Linda Kim May 2019 Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood Linda Kim This Thesis has been presented to and accepted by the Office of Graduate Studies, John Jay College of Criminal Justice in Partial Fulfillment of the Requirements for the Degree of Master of Science in Forensic Science. Thesis Committee Thesis Advisor: Marta Concheiro-Guisan Second Reader: Shu-Yuan Cheng External Reader: Damon Borg i Acknowledgement I would like to thank Dr. Stripp for providing his laboratory for my research, and Dr. Borg and everyone in Cordant Laboratory for their guidance and support. I would like to thank Dr. Concheiro-Guisan for her time, patience, and information, and for making it possible to successfully complete this thesis.
    [Show full text]
  • Skeletal Muscle Relaxants Review 12/17/2008
    Skeletal Muscle Relaxants Review 12/17/2008 Copyright © 2007 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Blood Thinners These Medications Require up to 2 Weeks of Discontinued Use Prior to a Myelogram Procedure
    MEDICATIONS TO AVOID PRE & POST MYELOGRAMS Radiocontrast agents used in myelography have the ability to lower the seizure threshold and when used with other drugs that also have this ability, may lead to convulsions. Drugs that possess the ability to lower seizure threshold should be discontinued at least 48 hours prior to myelography if possible and should not be resumed until at least 24 hours post-procedure. Drugs are listed below. ***Always consult with your prescribing physician prior to stoppage of your medication. Phenothiazines Antidepressants MAO Inhibitors Acetophenazine (Tindal) Amitriptyline (Elavil) Furazolidone (Furoxone) Chlorpromazine (Thorazine) Amoxapine (Asendin) Isocarboxazid (Marplan) Promethazine (Phenergan) Bupropion *(Welbutrin, Zyban) Pargyline (Eutonyl) Ethopropazine (Parsidol) Clomipramine (Anafranil, Placil) Phenelzine (Nardil) Fluphenazine (Prolixin) Desipramine (Norapramin) Procarbazine (Matulane) Mesoridazine (Serentil) Doxepin (Sinequan) Tranlcypromine (Parnate) Methdilazine (Tacaryl) Imipramine (Tofranil) Perphenazine (Trilafon) Maprotiline (Ludiomil) CNS Stimulants Proclorperazine (Compazine) Nortriptyline (Pamelor) Amphetamines Promazine (Sparine) Protriptyline (Vivactil) Pemoline (Cylert) Promethazine (Phenergan) Trimipramine (Surmontil) Thiethylperazine (Torecan) Thioridazine (Mellaril) Combination Antidepressants Trifluoperazine (Stelazine) Amitriptyline + Chlordiazepoxide (Limbitrol DS) Triflupromazine (Vesprin) Amitriptyline + Perphenazine (Triavil) Largon Levoprome Miscellaneous Antipsychotics
    [Show full text]
  • CYCLOBENZAPRINE (Brand Name: Flexeril®, Amrix®)
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section CYCLOBENZAPRINE ® ® (Brand Name: Flexeril , Amrix ) March 2020 Introduction: Illicit Uses: Cyclobenzaprine is a central nervous system Anecdotal reports found on the Internet suggest (CNS) muscle relaxant intended for short-term use that individuals are taking cyclobenzaprine alone or in the treatment of pain, tenderness and limitation of in combination with other illicit drugs to produce or motion caused by muscle spasms. Cyclobenzaprine enhance psychoactive effects. Individuals have may enhance the effects of other CNS depressants reported taking cyclobenzadrine both orally and including alcohol, barbiturates, benzodiazepines intra-nasally at doses ranging from 10 mg to 60 mg. and narcotics and anecdotal reports indicate it is Sedation, relaxation and increased heart rate were used non-medically to induce euphoria and the most common effects reported. Euphoria was relaxation. reported by a smaller number of individuals. Licit Uses: Illicit Distribution: Cyclobenzaprine hydrochloride is approved for Several indicators suggest that cyclobenzaprine use in the United States as a muscle relaxant. It is is being intentionally misused or abused. According marketed under the brand names Flexeril® and to the American Association of Poison Control Amrix® and as generic formulations in 5, 7.5, and 10 Centers, 10,615 case mentions and 4,444 single mg tablets intended for short-term (2 to 3 week) oral exposures were associated with cyclobenzaprine in administration. The usual starting dose is 5 mg, 2016, resulting in 75 major medical outcomes and three times per day. The maximum recommended four deaths among single substance exposures. In dose is 10 mg, three times daily.
    [Show full text]
  • Anaesthetic Implications of Calcium Channel Blockers
    436 Anaesthetic implications of calcium channel Leonard C. Jenkins aA MD CM FRCPC blockers Peter J. Scoates a sc MD FRCPC CONTENTS The object of this review is to emphasize the anaesthetic implications of calcium channel block- Physiology - calcium/calcium channel blockers Uses of calcium channel blockers ers for the practising anaesthetist. These drugs have Traditional played an expanding role in therapeutics since their Angina pectoris introduction and thus anaesthetists can expect to see Arrhythmias increasing numbers of patients presenting for anaes- Hypertension thesia who are being treated with calcium channel Newer and investigational Cardiac blockers. Other reviews have emphasized the basic - Hypertrophic cardiomyopathy pharmacology of calcium channel blockers. 1-7 - Cold cardioplegia - Pulmonary hypertension Physiology - calcium/calcium channel blockers Actions on platelets Calcium plays an important role in many physio- Asthma Obstetrics logical processes, such as blood coagulation, en- - Premature labor zyme systems, muscle contraction, bone metabo- - Pre-eclampsia lism, synaptic transmission, and cell membrane Achalasia and oesophageal spasm excitability. Especially important is the role of Increased intraocular pressure therapy calcium in myocardial contractility and conduction Protective effect on kidney after radiocontrast Cerebral vasospasm as well as in vascular smooth muscle reactivity. 7 Induced hypotensive anaesthesia Thus, it can be anticipated that any drug interfering Drag interactions with calcium channel blockers with the action of calcium could have widespread With anaesthetic agents effects. Inhalation agents In order to understand the importance of calcium - Effect on haemodynamics - Effect on MAC in cellular excitation, it is necessary to review some Neuromuscular blockers membrane physiology. Cell membranes are pri- Effects on epinephrine-induced arrhythmias marily phospholipids arranged in a bilayer.
    [Show full text]
  • Medications to Be Held for Allergy Skin Testing
    Your appointment with Dr. Jill Poole, Dr. Sara May or Dr. Andrew Rorie Dr. Joel VanDeGraaff is scheduled for: _______________________ MEDICATIONS TO BE HELD FOR ALLERGY SKIN TESTING ANTIHISTAMINES (TO BE HELD FOR 5 DAYS): Clarinex (desloratidine) Claritin (loratidine) Allegra (fexofenadine) Chlor-Trimeton (chlorpheneramine) Dexchlorpheniramine Benadryl (diphenhydramine) Zyrtec (cetirizine) Xyzal (levocetirizine) Brovex (brompheniramine) Dimetapp Actifed Periactin (cyproheptadine) Drixoral (dexbrompheniramine) Please check your over the counter medications to see if they include an antihistamine EYE DROPS (TO BE HELD FOR 5 DAYS): Bepreve (bepotastine) Zaditor (ketotifen) Optivar (azelastine) Patanol/Pataday/Pazeo (olopatadine) All over the counter eye drops with antihistamine-A TOPICAL STEROID ANTI-INFLAMMATORIES (TO BE HELD FOR 5 DAYS): (Gels, Creams, Ointments, Solutions, and Lotions) ORAL PREDNISONE Ideally off oral steroids for two weeks; however, skin testing can be completed while on oral steroid use at less than 20 mg daily. ANTIDEPRESSANTS (TO BE HELD FOR 1-2 WEEKS AS APPROVED WITH PCP): Elavil (amitryptiline) Doxepin Trimipramine Desipramine Remeron (mirtazapine) Trazodone Serzone (nefazodone) Asendin (amoxapine) Pamelor (nortriptyline) Imipramine NASAL SPRAYS (TO BE HELD FOR 5 DAYS): Astelin (azelastine) Patanase (olopatadine) Astelin/Astepro (azelastine) Dymista HISTAMINE BLOCKERS (TO BE HELD FOR 1 DAY): Tagamet (cimetidine) Zantac (ranitidine) Axid (nizatidine) Pepcid (famotidine) OTHERS (TO BE HELD THE NIGHT BEFORE): Singulair (montelukast) Zyflo (zileuton) Accolate (zafirlukast) OTHERS (TO BE HELD 4-7 DAYS BEFORE): Vistaril/Atarax (hydroxyzine) Phenergan (promethazine) Xanax (alprazolam) Klonopin (clonazepam) Flexeril (cyclobenzaprine) Antivert/Bonine (meclizine) Tylenol Cold & Sinus *If you have any questions, please call 402-559-4015 and ask to speak to a Allergy nurse. .
    [Show full text]
  • Assessment of Cyclobenzaprine in the Treatment of Spasticity
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.35.5.599 on 1 October 1972. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry, 1972, 35, 599-605 Assessment of cyclobenzaprine in the treatment of spasticity PETER ASHBY, DAVID BURKE, SUDHAKAR RAO, AND RICHARD F. JONES From the Division of Neurology and the Department of Rehabilitation Medicine, Prince Henry Hospital, Sydney, Australia SUMMARY The efficacy of cyclobenzaprine 60 mg/day in the treatment of spasticity was assessed in a double-blind crossover trial of two weeks' duration in 15 patients suffering from cerebral or spinal spasticity. Independent clinical and electromyographic methods were used. The effects of cyclobenzaprine did not differ significantly from those of placebo. The administration of a higher dosage, 150 mg/day, to one patient revealed a dose-related response, but the degree of improvement was clinically small. Apart from a skin rash there were no significant untoward effects of therapy. Pharmacological agents play a small but signifi- no untoward side-effects in oral dosage of up to cant role in the management of the spastic 600 mg/day and intravenous dosage of 15 mg Protected by copyright. patient. Effective spasmolytic agents are valuable (Merck, Sharp and Dohme Research Labora- in the early stages following spinal cord trauma tories, personal communication). where spasticity makes nursing management Assessment of the efficacy of medication for difficult, when independent use of a wheelchair the relief of hypertonia must rely on clinical is threatened by deforming postures, and, most evaluation, despite potential observer incon- importantly, in the maintenance of a degree of sistency.
    [Show full text]